Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis

References

• Sedlacek HH. Kinase inhibitors in cancer therapy: a look ahead. Drugs 2000;59:435–76.
   PubMed Web of Science ®Google Scholar
• Wells A. EGF receptor. Int J Biochem Cell Biol 1999;31:637–43.
   PubMed Web of Science ®Google Scholar
• Perry JE, Grossman ME, Tindall DJ. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate 1998;35:117–24.
   PubMed Web of Science ®Google Scholar
• Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 2000;59:753–67.
   PubMed Web of Science ®Google Scholar
• Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241–50.
   PubMed Web of Science ®Google Scholar
• Zhau HE, Zhang X, von Eschenbach AC, et al. Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog 1990;3:254–7.
   PubMed Web of Science ®Google Scholar
• Kapitanovic S, Radosevic S, Kapitanovic M, et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997;112:1103–13.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–12.
   PubMed Web of Science ®Google Scholar
• Brignola PS, Lackey K, Kadwell SH, et al. Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors. J Biol Chem 2002;277:1576–85.
   PubMed Web of Science ®Google Scholar
• Moulder SL, Yakes FM, Muthuswamy SK, et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887–95.
   PubMed Web of Science ®Google Scholar
• Manstein V, Yang C, Richter D, et al. Resistance of cancer cells to targeted therapies through the activation of compensating signaling loops. Curr Signal Trans Ther 2013;8:193–202.
   PubMed Web of Science ®Google Scholar
• Smith JE. Small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin Therapeut 2005;27:1513–34.
   PubMed Web of Science ®Google Scholar
• Simon GR, Ruckdeschel JC, Williams C, et al. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution, Cancer control. J Moffitt Cancer Center 2003;10:388–95.
   PubMedGoogle Scholar
• Burris HA. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004;9:10–15.
   PubMed Web of Science ®Google Scholar
• Gray NS, Wodicka L, Thunnissen AMWH, et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998;281:533–8.
   PubMed Web of Science ®Google Scholar
• Chauhan M, Kumar R. Medicinal attributes of pyrazolo[3,4-d]pyrimidines: a review. Bioorg Med Chem 2013;21:5657–68.
   PubMed Web of Science ®Google Scholar
• Petrie CR, Cottam HB, Mckernan PA, et al. Synthesis and biological activity of 6-azacadeguomycin and certain 3,4,6-trisubstituted pyrazolo[3,4-d]pyrimidine ribonucleosides. J Med Chem 1985;28:1010–6.
   PubMed Web of Science ®Google Scholar
• Traxler P, Bold G, Buchdunger E, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001;21:499–512.
   PubMed Web of Science ®Google Scholar
• Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004;64:4931–41.
   PubMed Web of Science ®Google Scholar
• Wang GT, Mantei RA, Hubbard RD, et al. Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases. Bioorg Med Chem Lett 2010;20:6067–71.
   PubMed Web of Science ®Google Scholar
• Ducray R, Ballard P, Barlaam BC, et al. Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and ErbB2 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2008;18:959–62.
   PubMed Web of Science ®Google Scholar
• Hagmann WK. The many roles for fluorine in medicinal chemistry. J Med Chem 2008;51:4359–69.
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Konoki K, Murata M, et al. Design, synthesis, and biological evaluation of fluorinated analogues of salicylihalamide. J Med Chem 2009;52:798–806.
   PubMed Web of Science ®Google Scholar
• Balakumar C, Lamba P, Kishore DP, et al. Synthesis, anti-inflammatory evaluation and docking studies of some new fluorinated fused quinazolines. Eur J Med Chem 2010;45:4904–13.
   PubMed Web of Science ®Google Scholar
• Kassab AE, Gedawy EM. Synthesis and anticancer activity of novel 2-pyridyl hexahyrocyclooctathieno[2,3-d]pyrimidine derivatives. Eur J Med Chem 2013;63:224–30.
   PubMed Web of Science ®Google Scholar
• Kassab AE, Gedawy EM, El-Malah AA, et al. Synthesis, anticancer activity, effect on cell cycle profile, and apoptosis-inducing ability of novel hexahydrocyclooctathieno[2,3-d]-pyrimidine derivatives. Chem Pharm Bull 2016;64:490–6.
   PubMed Web of Science ®Google Scholar
• Alley MC, Scudiero DA, Monks PA, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589–601.
   PubMed Web of Science ®Google Scholar
• Grever MR, Schepartz SA, Chabner BA. The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 1992;19:622–38.
   PubMed Web of Science ®Google Scholar
• Boyd MR, Paull KD. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Develop Res 1995;34:91–109.
   Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
   PubMed Web of Science ®Google Scholar
• Tolba MF, Esmat A, Al-Abd AM, et al. Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells. Int Union Biochem Mol Biol 2013;65:716–29.
   Web of Science ®Google Scholar
• Urushibara Y, Takebayashi M. The nitrile-esters of 2-methylpropene-1,1,3,3-tetracarboxylic acid. Bull Chem Soc Jpn 1936;11:557–68.
   Google Scholar
• Faria JV, dos Santos MS, Bernardino AMR, et al. Synthesis and activity of novel tetrazole compounds and their pyrazole-4-carbonitrile precursors against Leishmania spp. Bioorg Med Chem Lett 2013;23:6310–2.
   PubMed Web of Science ®Google Scholar
• Lee MJ, Ye AS, Gardino AK, et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012;149:780–94.
   PubMed Web of Science ®Google Scholar
• Carpenter RL, Lo HW. Regulation of apoptosis by HER2 in breast cancer. J Carcinog. Mutagen 2013;2013:1–6.
   Google Scholar
• Vermes I, Haanen C, Steffens-Nakken H, Reutellingsperger C. A novel assay for apoptosis Flow cytometric detection of phosphatidylserine early apoptotic cells using fluorescein labelled expression on Annexin V. J Immunol Methods 1995;184:39–51.
   PubMed Web of Science ®Google Scholar